Oura IPO Can a smart ring become a health platform

中文标题

Oura IPO：智能戒指能否成为健康平台

Saxo Bank09/29/2026updated 10/17/2026

Unknown economy

Citable research brief

Core conclusion · Tlines extraction

Oura is listing on Nasdaq (OURA) with 50 million shares at US$40-44, implying roughly US$13.5 billion market value, about 9.5x trailing sales and over 200x trailing earnings. Nine-month FY2026 revenue rose 74% to US$1.21 billion, net income US$60.8 million, gross margin 55%, and 5 million paid members should reach about 5.7 million by year-end. Subscription growth and health partnerships support the platform narrative, but hardware still supplies around 80% of revenue and only 13.5 million shares are new primary issuance.

Institution: Saxo Bank
Published: 09/29/2026
Research topic: Nasdaq 100
Time horizon: June 2026

Nasdaq 100 · NDX

Key arguments

Rapid growth with positive earnings differentiates Oura from many high-growth technology IPOs, though current profit remains small versus valuation.
Membership revenue is the faster-growing, higher-quality layer: up 121% year-on-year to US$240.5 million, now 20% of revenue, supported by about 85% 12-month paid-member retention.
Healthcare partnerships with Dexcom, Eli Lilly and Resmed lend credibility to a preventative-health platform strategy, but remain mostly ahead rather than in reported revenue.
The offering mainly creates shareholder liquidity and settles employee equity obligations; large-platform competition and regulatory, privacy and cybersecurity exposure are key risks.

Key numbers

IPO price range: US$40-44 per share
Shares offered: 50 million, of which 13.5 million primary and 36.5 million secondary
Implied market capitalisation: About US$13.5 billion at US$42 midpoint
Valuation multiples: About 9.5x trailing sales; over 200x trailing earnings
Nine-month FY2026 financials: Revenue US$1.21 billion (+74%); net income US$60.8 million; gross margin 55%

Main risks

Apple, Google and Samsung can bundle wearables with phones, operating systems and health platforms, giving distribution and ecosystem advantages Oura cannot easily replicate.
Hardware remains about 80% of revenue; if subscription penetration stalls or customer acquisition costs rise, margin expansion becomes harder.
Deeper healthcare expansion raises regulatory, cybersecurity and privacy exposure around sensitive biometric data.

Corresponding source evidence

Revenue rose 74% year-on-year to US$1.21 billion in the nine months to June 2026, gross margin improved to 55%, and net income reached US$60.8 million. · June 2026
Oura is preparing to list on Nasdaq under the ticker OURA, with 50 million shares offered at an expected price of US$40–44 each.
Oura now expects paid membership to reach around 5.7 million by the end of FY2026.

Context: the conclusion is Tlines' automated extraction, not the institution's wording. Quoted evidence is publisher wording. Scope and date must travel with the conclusion.

Verify at the original source ↗